All In Biotech

Drug Trial Radar · NCT05108922

A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)

A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

148

Actual

Start

Nov 16, 2021

Primary completion

Sep 9, 2022

Study completion Sep 19, 2023

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).

Conditions

  • Mild Cognitive Impairment (MCI)
  • Alzheimer Disease

Interventions

  • DonanemabDrug

    Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.

  • AducanumabDrug

    Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus AducanumabTime frame: 6 Months
  2. Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus AducanumabTime frame: 6 Months

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Neurology Center of North Orange County

    Fullerton, California

  • Irvine Clinical Research

    Irvine, California

  • California Neuroscience Research Medical Group, Inc.

    Sherman Oaks, California

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • JEM Research Institute

    Atlantis, Florida

  • Brain Matters Research

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • Infinity Clinical Research, LLC

    Hollywood, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Charter Research - Lady Lake

    Lady Lake, Florida

  • ClinCloud - Maitland

    Maitland, Florida

  • ClinCloud - Viera

    Melbourne, Florida

  • Merritt Island Medical Research, LLC

    Merritt Island, Florida

  • Optimus U Corporation

    Miami, Florida

  • Brainstorm Research

    Miami, Florida

  • Brain Matters Research

    Stuart, Florida

  • Axiom Clinical Research of Florida

    Tampa, Florida

  • Conquest Research

    Winter Park, Florida

  • Columbus Memory Center, PC

    Columbus, Georgia

  • Josephson Wallack Munshower Neurology, PC

    Indianapolis, Indiana

  • Donald S. Marks M.D., P.C.

    Plymouth, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • Clinical Research Professionals

    Chesterfield, Missouri

  • Las Vegas Medical Research

    Las Vegas, Nevada

  • The Cognitive and Research Center of New Jersey

    Springfield, New Jersey

  • Advanced Memory Research Institute of New Jersey

    Toms River, New Jersey

  • Neurology Diagnostics, Inc.

    Dayton, Ohio

  • Abington Neurological Associates, Ltd.

    Abington, Pennsylvania

  • The Clinical Trial Center, LLC

    Jenkintown, Pennsylvania

  • Kerwin Medical Center

    Dallas, Texas

  • National Clinical Research, Inc

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.